Read Time:45 Second
On August 7, 2025, the U.S. Food and Drug Administration (FDA) approved the SetPoint System, a new neuroimmune modulation device designed to treat adults suffering from moderate-to-severe rheumatoid arthritis (RA).
This innovative device aims to improve the quality of life for RA patients by targeting nerve pathways that influence the immune system. The SetPoint System offers a fresh approach to managing symptoms associated with this chronic inflammatory disorder.
Developed as an alternative for patients who have not responded well to traditional medications, this approval marks a significant advancement in rheumatoid arthritis treatment options in the USA.
The device works by:
- Modulating neural signals
- Reducing inflammation
- Alleviating joint pain
These effects potentially offer relief without the side effects commonly seen with drug therapies. Medical professionals anticipate that the SetPoint System will become a valuable option in comprehensive RA care.
Stay tuned to Questiqa USA for more latest updates.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating